PGEN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

8.29M

+596.27%

-0.084

+68.04%

21.20M

+1480.91%

-0.075

-58.33%

27.00M

+3054.21%

-0.055

-38.89%

Estimates Revision

The market is revising Upward the revenue expectations for Precigen, Inc. (PGEN) for FY2025, with the revenue forecasts being adjusted by 0.09% over the past three months. During the same period, the stock price has changed by 47.49%.

Revenue Estimates for FY2025

Revise Upward

+0.09%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+121.27%

In Past 3 Month

Stock Price

Go Up

+47.49%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast PGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PGEN is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

9.00

Averages

9.00

High

9.00

Current: 0.000

Low

9.00

Averages

9.00

High

9.00

H.C. Wainwright

Buy

maintain

2025-11-14

Reason

H.C. Wainwright

Price Target

2025-11-14

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Precigen to $9 from $8.50 and keeps a Buy rating on the shares post the Q3 report. The firm says the Papzimeos launch is generating a "robust" pipeline of patients.

Citizens JMP

Outperform

maintain

$6 -> $8

2025-08-19

Reason

Citizens JMP

Price Target

$6 -> $8

2025-08-19

maintain

Outperform

Reason

Citizens JMP raised the firm's price target on Precigen to $8 from $6 and keeps an Outperform rating on the shares. Precigen discussed the approval of PAPZIMEOS for the treatment of respiratory papillomatosis, as well as the price, with a wholesale acquisition cost of $460k per patient, higher than the firm's prior assumption of $200k per patient, the analyst tells investors in a research note.

JPMorgan

Underweight -> Neutral

upgrade

$NULL

2025-08-15

Reason

JPMorgan

Price Target

$NULL

2025-08-15

upgrade

Underweight -> Neutral

Reason

JPMorgan upgraded Precigen to Neutral from Underweight without a price target following the FDA's approval of Papzimeos. The firm cites the removal of Precigen's "major regulatory overhang" and its revenue potential for the upgrade. However, the adoption of Papzimeos will take time to materialize, the analyst tells investors in a research note. JPMorgan believes that with limited cash on the balance sheet to support the launch, further dilution post approval is "likely inevitable" for Precigen.

H.C. Wainwright

Buy

upgrade

2025-08-15

Reason

H.C. Wainwright

Price Target

2025-08-15

upgrade

Buy

Reason

H.C. Wainwright raised the firm's price target on Precigen to $8.50 from $6 and keeps a Buy rating on the shares following FDA approval of Papzimeos for the treatment of recurrent respiratory papillomatosis. The firm did not expect an approval to come nearly two weeks earlier than the action date of August 27. The FDA's "unprecedented way" of providing full approval without a need for a randomized study underscores the unmet need in RPR, the analyst tells investors in a research note. H.C. Wainwright expects the drug to generate sales of $1.1B in 2033 from $138M in 2026.

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

2025-03-20

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

2025-03-20

Reiterates

Strong Buy

Reason

Citizens Capital Markets

Jason Butler

Buy

Reiterates

2025-03-20

Reason

Citizens Capital Markets

Jason Butler

Price Target

2025-03-20

Reiterates

Buy

Reason

Valuation Metrics

The current forward P/E ratio for Precigen Inc (PGEN.O) is -17.91, compared to its 5-year average forward P/E of -6.06. For a more detailed relative valuation and DCF analysis to assess Precigen Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.06

Current PE

-17.91

Overvalued PE

1.37

Undervalued PE

-13.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.79

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

3.29

Undervalued EV/EBITDA

-4.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

34.39

Current PS

16.89

Overvalued PS

67.86

Undervalued PS

0.92

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 801.59% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PGEN News & Events

Events Timeline

No data

News

1.0

01-05PRnewswire

Precigen CEO Helen Sabzevari to Present at 44th Annual J.P. Morgan Healthcare Conference

9.0

2025-12-29Benzinga

Ultragenyx Shares Plunge 42% Following Phase 3 Study Failures for Setrusumab

8.5

2025-12-29Benzinga

DigitalBridge Group Inc Acquired by SoftBank Group for Approximately $4 Billion

People Also Watch

Frequently Asked Questions

What is Precigen Inc (PGEN) stock price today?

The current price of PGEN is 4.705 USD — it has increased 2.06 % in the last trading day.

What is Precigen Inc (PGEN)'s business?

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

What is the price predicton of PGEN Stock?

What is Precigen Inc (PGEN)'s revenue for the last quarter?

Precigen Inc revenue for the last quarter amounts to 2.92M USD, increased 206.61 % YoY.

What is Precigen Inc (PGEN)'s earnings per share (EPS) for the last quarter?

Precigen Inc. EPS for the last quarter amounts to -1.06 USD, increased 1077.78 % YoY.

What changes have occurred in the market's expectations for Precigen Inc (PGEN)'s fundamentals?

How many employees does Precigen Inc (PGEN). have?

Precigen Inc (PGEN) has 143 emplpoyees as of January 09 2026.

What is Precigen Inc (PGEN) market cap?

Today PGEN has the market capitalization of 1.63B USD.